AI ScreeningAI ChatPricing
  1. JP-listed companies
  2. SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
  3. Financials
  4. Pretax margin (%)

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.【JP:2395】

Market cap
¥64.4B
P/E ratio
18.1x
Provides drug development testing services to pharmaceutical companies and operates innovative intranasal drug delivery technology through spinout companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Mar 31, 202519.9-24.97%
Mar 31, 202426.5-27.61%
Mar 31, 202336.6-8.12%
Mar 31, 202239.9+65.31%
Mar 31, 202124.1+12.54%
Mar 31, 202021.4+108.01%
Mar 31, 201910.3-310.40%
Mar 31, 2018-4.9-59.89%
Mar 31, 2017-12.2-65.76%
Mar 31, 2016-35.7-4185.64%
Mar 31, 20150.9-195.90%
Mar 31, 2014-0.9-68.15%
Mar 31, 2013-2.9-84.65%
Mar 31, 2012-18.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)